Filing Details
- Accession Number:
- 0001567619-20-020620
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-12-03 19:40:50
- Reporting Period:
- 2020-12-01
- Accepted Time:
- 2020-12-03 19:40:50
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1787306 | Arcutis Biotherapeutics Inc. | ARQT | Pharmaceutical Preparations (2834) | 812974255 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1801050 | G. Howard Welgus | C/O Arcutis Biotherapeutics, Inc. 2945 Townsgate Road, Suite 110 Westlake Village CA 91361 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-12-01 | 390 | $1.68 | 180,234 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2020-12-01 | 1,810 | $1.68 | 182,044 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-12-01 | 887 | $25.20 | 181,157 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-12-01 | 1,050 | $26.29 | 180,107 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-12-01 | 263 | $27.36 | 179,844 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2020-12-01 | 390 | $0.00 | 390 | $1.68 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2020-12-01 | 1,810 | $0.00 | 1,810 | $1.68 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 13,667 | 2029-03-13 | No | 4 | M | Direct | |
| 30,962 | 2029-03-13 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 24,991 | Indirect | By Trust |
Footnotes
- Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- The transaction was executed in multiple trades in prices ranging from $24.64 to $25.44, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The transaction was executed in multiple trades in prices ranging from $25.88 to $26.82, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The transaction was executed in multiple trades in prices ranging from $26.95 to $27.59, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The securities are held of record by The Welgus Living Trust, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
- The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.
Billionaire Hedge Funds
